Form 4: Sarepta Therapeutics Executive Bilal Arif Reports Stock Transactions
SEC Form 4 Filing
Bilal Arif, Chief Tech Ops Officer at Sarepta Therapeutics, reports acquisition and disposal of company stock and stock options.
Summary
- Bilal Arif, a Chief Tech Ops Officer at Sarepta Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
- On March 10, 2025, Arif disposed of 523 shares of common stock at a price of $100.13 to cover tax obligations related to vesting of restricted stock units.
- On the same day, Arif acquired 8,276 shares of common stock through restricted stock units (RSUs).
- Arif also acquired 16,644 stock options with an exercise price of $99.69, vesting incrementally from March 10, 2026, and expiring on March 10, 2035.
- Following these transactions, Arif directly owns 24,224 shares of common stock and holds rights to 32,500 shares through RSUs, as well as 16,644 stock options.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The transactions are routine and reflect standard executive compensation practices. The acquisition of RSUs and stock options is a positive sign, while the sale of shares for tax obligations is a neutral event.
Positives
- The acquisition of 8,276 shares through RSUs indicates confidence in the company's future performance.
- The grant of 16,644 stock options incentivizes the executive to contribute to the company's long-term success.
Negatives
- The disposal of 523 shares, although for tax obligations, could be perceived negatively if not understood in context.
Risks
- There are no specific risks mentioned in this document, but standard risks associated with stock ownership and executive compensation apply.
Future Outlook
The vesting schedule of the RSUs and stock options suggests a long-term commitment by the executive to the company's success.
Industry Context
Executive stock transactions are common and are closely watched by investors for insights into management's confidence in the company's prospects. This filing is a routine disclosure.
Comparison to Industry Standards
- Executive compensation packages, including stock options and RSUs, are standard practice in the biotechnology industry to align management's interests with those of shareholders.
- Companies like Biogen, Vertex Pharmaceuticals, and Amgen also utilize similar equity-based compensation strategies.
- The vesting schedules and exercise prices are generally in line with industry norms for companies of Sarepta's size and stage.
Stakeholder Impact
- Shareholders may view the executive's stock transactions as an indicator of confidence in the company.
- Employees may see the equity-based compensation as a positive aspect of working at Sarepta.
Key Dates
| Date | Description |
|---|---|
| 03/07/2022 | Date of grant for restricted stock units, which vest over four years. |
| 03/10/2025 | Date of the reported transactions: stock disposal, RSU acquisition, and stock option acquisition. |
| 03/11/2025 | Date of signature for the Form 4 filing. |
| 03/10/2026 | Date upon which the first 25% of the option granted vests. |
| 03/10/2035 | Expiration date of the acquired stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.